A. Bergamo

发表

Ruthenium-porphyrin conjugates with cytotoxic and phototoxic antitumor activity.

C. Spagnul, I. Bratsos, T. Gianferrara, 2010, Journal of medicinal chemistry.

Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin

A. Bergamo, G. Sava, L. Messori, 2003, Investigational New Drugs.

Chitosan-coated alginate micro-particles delivery of active principles through conventional pelleted food - A study in Tilapia (Oreochromis niloticus).

A. Bergamo, G. Sava, E. Giacomello, 2020, International journal of biological macromolecules.

Distinct Effects of Dinuclear Ruthenium(III) Complexes on Cell Proliferation and on Cell Cycle Regulation in Human and Murine Tumor Cell Lines

A. Bergamo, G. Sava, E. Alessio, 2003, Journal of Pharmacology and Experimental Therapeutics.

Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound.

P. Dyson, A. Bergamo, G. Sava, 2008, International journal of oncology.

Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A

D. Ribatti, A. Bergamo, G. Sava, 2002, British Journal of Cancer.

Towards Matched Pairs of Porphyrin–ReI/99mTcI Conjugates that Combine Photodynamic Activity with Fluorescence and Radio Imaging

S. Ferrari, G. Gasser, C. Spagnul, 2014, ChemMedChem.

Synthesis, characterization and tumor cell growth inhibition of new trans platinum complexes with phosphane derivatives

A. Bergamo, G. Sava, A. Quiroga, 2011 .

Age Dependent Modification of the Metabolic Profile of the Tibialis Anterior Muscle Fibers in C57BL/6J Mice

C. Reggiani, L. Toniolo, L. Torelli, 2020, International journal of molecular sciences.

Photolabile RuII Half-Sandwich Complexes Suitable for Developing “Caged” Compounds: Chemical Investigation and Unexpected Dinuclear Species with Bridging Diamine Ligands

I. Bratsos, N. Demitri, T. Gianferrara, 2013 .

New half sandwich-type Ru(II) coordination compounds characterized by the fac-Ru(dmso-S)3 fragment: influence of the face-capping group on the chemical behavior and in vitro anticancer activity.

E. Zangrando, I. Bratsos, T. Gianferrara, 2011, Dalton transactions.

Down‐regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an anti‐metastatic ruthenium complex

A. Bergamo, G. Sava, E. Alessio, 1996, International journal of cancer.

Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.

B. Keppler, P. Dyson, A. Bergamo, 2007, Dalton transactions.

Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging Properties

A. Bergamo, G. Sava, S. Zorzet, 2016, International journal of molecular sciences.

CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2

R. Bataille, C. Pellat-deceunynck, A. Bergamo, 1997, British journal of haematology.

Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

J. Schellens, J. Beijnen, A. Bergamo, 2012, Journal of inorganic biochemistry.

Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.

G. Pezzoni, A. Bergamo, G. Sava, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation

E. Zangrando, A. Bergamo, G. Sava, 2008, JBIC Journal of Biological Inorganic Chemistry.

In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model.

Anna F. A. Peacock, P. Sadler, A. Habtemariam, 2010, Journal of inorganic biochemistry.

Solution, solid state and biological characterization of ruthenium(III)-DMSO complexes with purine base derivatives.

I. Turel, A. Bergamo, G. Sava, 2004, Journal of inorganic biochemistry.

Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).

J. G. Haasnoot, E. Zangrando, A. Bergamo, 2004, Journal of Medicinal Chemistry.

Thrombotic events with or without thrombocytopenia in recipients of adenovirus-based COVID-19 vaccines

A. Bergamo, G. Sava, S. Pierno, 2022, Frontiers in Cardiovascular Medicine.

Influence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds

I. Tavernelli, U. Rothlisberger, P. Dyson, 2006 .

In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.

P. Dyson, G. Laurenczy, A. Bergamo, 2005, Journal of medicinal chemistry.

Half-sandwich Ru II[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: preparation, structural characterization and in vitro cytotoxic activity.

E. Zangrando, I. Bratsos, T. Gianferrara, 2008, Journal of inorganic biochemistry.

Is the Aromatic Fragment of Piano‐Stool Ruthenium Compounds an Essential Feature for Anticancer Activity? The Development of New RuII‐[9]aneS3 Analogues

P. Dyson, E. Zangrando, T. Gianferrara, 2005 .

Synthesis, catalytic properties and biological activity of new water soluble ruthenium cyclopentadienyl PTA complexes [(C5R5)RuCl(PTA)2] (R = H, Me; PTA = 1,3,5-triaza-7-phosphaadamantane).

M. Peruzzini, F. Vizza, A. Bergamo, 2003, Chemical communications.

Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenanthrolines and acyclovir or penciclovir.

E. De Clercq, N. Margiotta, G. Natile, 2004, Journal of inorganic biochemistry.

Synthesis, characterization and biological activity of copper complexes with pyridoxal thiosemicarbazone derivatives. X-ray crystal structure of three dimeric complexes.

S. Pinelli, A. Bergamo, G. Sava, 2004, Journal of inorganic biochemistry.

Synthesis and characterization of a diruthenium(II,III)–ketoprofen compound and study of the in vitro effects on CRC cells in comparison to the naproxen and ibuprofen derivatives

A. Bergamo, G. Sava, R. Santos, 2012 .

Phototoxic Activity and DNA Interactions of Water‐Soluble Porphyrins and Their Rhenium(I) Conjugates

Ramon Vilar, Gilles Gasser, Vanessa Pierroz, 2015, ChemMedChem.

Rhodium(III) analogues of antitumour-active ruthenium(III) compounds: The crystal structure of [ImH][trans-RhCl4(Im)2] (Im=imidazole)

A. Bergamo, G. Sava, E. Alessio, 1998 .

Metal-based antitumour drugs in the post-genomic era: what comes next?

P. Dyson, A. Bergamo, G. Sava, 2011, Dalton transactions.

Ruthenium-based compounds and tumour growth control (review).

A. Bergamo, G. Sava, 2000, International journal of oncology.

Molecular structure, solution chemistry and biological properties of the novel [ImH][trans-IrCl(4)(Im)(DMSO)], (I) and of the orange form of [(DMSO)(2)H][trans-IrCl(4)(DMSO)(2)], (II), complexes.

A. Bergamo, G. Sava, L. Messori, 2003, Journal of inorganic biochemistry.

Ruthenium anticancer drugs.

A. Bergamo, G. Sava, E. Alessio, 2004, Metal ions in biological systems.

Biological Properties of IRIM, the Iridium(III) Analogue of (Imidazolium (Bisimidazole) Tetrachlororuthenate) (ICR)

A. Casini, A. Bergamo, L. Messori, 2000, Metal-based drugs.

Linking the future of anticancer metal-complexes to the therapy of tumour metastases.

A. Bergamo, G. Sava, Alberta Bergamo, 2015, Chemical Society reviews.

The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions

P. Dyson, A. Bergamo, G. Sava, 2018 .

Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.

A. Bergamo, G. Sava, 2011, Dalton transactions.

Ruthenium antimetastatic agents.

A. Bergamo, G. Sava, E. Alessio, 2004, Current topics in medicinal chemistry.

Sulfoxide Ruthenium Complexes: Non-Toxic Tools for the Selective Treatment of Solid Tumour Metastases

A. Bergamo, G. Sava, E. Alessio, 1999 .

Ruthenium complexes can target determinants of tumour malignancy.

A. Bergamo, G. Sava, 2007, Dalton transactions.

Platinum(II) complexes with antitumoral/antiviral aromatic heterocycles: effect of glutathione upon in vitro cell growth inhibition.

N. Margiotta, G. Natile, A. Bergamo, 2005, Journal of medicinal chemistry.

Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine.

A. Bergamo, G. Sava, E. Alessio, 1999, Anticancer research.

Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes.

A. Bergamo, G. Sava, E. Alessio, 2000, The Journal of pharmacology and experimental therapeutics.

Ruthenium Drugs for Cancer Chemotherapy: An Ongoing Challenge to Treat Solid Tumours

A. Bergamo, G. Sava, 2009 .

Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[[trans-RuCl4(Me2SO)]2(mu-L)] (L = ditopic, non-chelating aromatic N-ligand). A preliminary investigation.

A. Bergamo, G. Sava, E. Alessio, 2000, Journal of inorganic biochemistry.

Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition.

A. Bergamo, G. Sava, E. Alessio, 1995, Chemico-biological interactions.

Lysozyme stimulates lymphocyte response to ConA and IL-2 and potentiates 5-fluorouracil action on advanced carcinomas.

A. Bergamo, G. Sava, S. Pacor, 1995, Anticancer research.

Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.

A. Bergamo, G. Sava, E. Alessio, 2002, European journal of cancer.

In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.

A. Bergamo, G. Sava, E. Alessio, 1999, The Journal of pharmacology and experimental therapeutics.

Modulation of Activity of Known Cytotoxic Ruthenium(III) Compound (KP418) with Hampered Transmembrane Transport in Electrochemotherapy In Vitro and In Vivo

D. Miklavčič, B. Keppler, M. Čemažar, 2014, The Journal of Membrane Biology.

Novel platinum pyridinehydroxamic acid complexes: Synthesis, characterisation, X-ray crystallographic study and nitric oxide related properties

A. Bergamo, G. Sava, H. Müller‐Bunz, 2007 .

Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A.

A. Chambery, A. Bergamo, G. Sava, 2017, Journal of inorganic biochemistry.

Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A.

B. Codan, A. Bergamo, G. Sava, 2016, Journal of inorganic biochemistry.

RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A.

M. Gerdol, A. Pallavicini, A. Bergamo, 2015, Metallomics : integrated biometal science.

Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process

A. Bergamo, G. Sava, A. Masi, 2015, JBIC Journal of Biological Inorganic Chemistry.

Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.

V. Brabec, A. Bergamo, G. Sava, 2015, Dalton transactions.

Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion

M. Jakupec, B. Keppler, A. Bergamo, 2009, Metal-based drugs.

The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy.

P. Dyson, I. Khalaila, A. Bergamo, 2006, International journal of oncology.

Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells

A. Bergamo, G. Sava, V. Scarcia, 2002, Cancer Chemotherapy and Pharmacology.

Tumour cell uptake G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells.

A. Bergamo, G. Sava, M. Carotenuto, 2001, Anticancer research.

Preclinical combination therapy of the investigational drug NAMI-A+ with doxorubicin for mammary cancer

P. Dyson, A. Bergamo, G. Sava, 2015, Investigational New Drugs.

Influence of the anionic ligands on the anticancer activity of Ru(II)-dmso complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors.

E. Zangrando, I. Bratsos, T. Gianferrara, 2008, Journal of inorganic biochemistry.

Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs.

G. Jaouen, A. Bergamo, G. Sava, 2012, Dalton transactions.

CDK1 hyperphosphorylation maintenance drives the time-course of G2-M cell cycle arrest after short treatment with NAMI-A in Kb cells.

A. Bergamo, G. Sava, C. Casarsa, 2012, Anti-cancer agents in medicinal chemistry.

Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells

A. Bergamo, G. Sava, E. Alessio, 2000, Anti-cancer drugs.

Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A.

A. Bergamo, G. Sava, M. Carotenuto, 2000, Anticancer research.

Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.

A. Bergamo, G. Sava, E. Alessio, 2002, International journal of oncology.

Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulfoxide-ruthenium compounds and cisplatin detected by flow cytometry.

A. Bergamo, G. Sava, M. Cocchietto, 1998, Chemico-biological interactions.

Drug control of solid tumour metastases: a critical view.

A. Bergamo, G. Sava, 1999, Anticancer research.

Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through α5β1 Integrin

A. Bergamo, G. Sava, H. Mollica, 2015, Journal of cellular biochemistry.

Lysozyme-Induced Transcriptional Regulation of TNF-α Pathway Genes in Cells of the Monocyte Lineage

M. Gerdol, A. Pallavicini, P. Dyson, 2019, International journal of molecular sciences.

Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data

A. Bergamo, G. Sava, S. Pierno, 2021, Journal of Autoimmunity.

New half sandwich Ru(II) coordination compounds for anticancer activity.

E. Zangrando, I. Bratsos, T. Gianferrara, 2012, Dalton transactions.

Reduction of Lung Metastases by Na[trans-RuCl4(DMSO)Im] is not Coupled With the Induction of Chemical Xenogenization

A. Bergamo, G. Sava, E. Alessio, 1996, Metal-based drugs.

Long Non-Coding RNA GAS5 and Intestinal MMP2 and MMP9 Expression: A Translational Study in Pediatric Patients with IBD

A. Bergamo, V. Villanacci, S. Martelossi, 2019, International journal of molecular sciences.

Long-term resveratrol treatment improves the capillarization in the skeletal muscles of ageing C57BL/6J mice

L. Toniolo, L. Torelli, A. Bergamo, 2020, International journal of food sciences and nutrition.

Novel water-soluble (99m)Tc(I)/Re(I)-porphyrin conjugates as potential multimodal agents for molecular imaging.

S. Ferrari, G. Gasser, C. Spagnul, 2013, Journal of inorganic biochemistry.

Interaction of NAMI-A with the regulation of cell cycle progression of tumour cells.

A. Bergamo, G. Sava, S. Zorzet, 2000 .

Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion.

A. Bergamo, G. Sava, E. Alessio, 2004, International journal of oncology.

Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.

A. Bergamo, G. Sava, 2011, Dalton transactions.

Selection of Natural Compounds with HMGA-Interfering Activities and Cancer Cell Cytotoxicity

M. Mori, G. Manfioletti, A. Bergamo, 2023, ACS omega.

Chemical and Molecular Approach to Tumor Metastases

A. Bergamo, G. Sava, 2018, International journal of molecular sciences.

Modulation of Activity of Known Cytotoxic Ruthenium(III) Compound (KP418) with Hampered Transmembrane Transport in Electrochemotherapy In Vitro and In Vivo

D. Miklavčič, B. Keppler, M. Čemažar, 2014, The Journal of Membrane Biology.

Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A.

A. Chambery, A. Bergamo, G. Sava, 2017, Journal of inorganic biochemistry.

Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process

A. Bergamo, L. Brescacín, Gianni Sava, 2015, JBIC Journal of Biological Inorganic Chemistry.

Pharmacological Modulation of Host Immunity with Hen Egg White Lysozyme (HEWL)—A Review

A. Bergamo, G. Sava, 2023, Molecules.